The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice


Alessandra Gambero, Clinical Pharmacology and Gastroenterology Unit, São Francisco University Medical School, Av. São Francisco de Assis 218, 12916-900, Bragança Paulista, São Paulo, Brazil Tel: +55 11 2454 8982
Fax: +55 11 2454 1825


Background: Pro-inflammatory cytokines, such as tumour necrosis factor (TNF)-α, are known to be involved in the establishment of insulin resistance. Insulin resistance plays a key role in the development of obesity-related pathologies, such as type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). The state of chronic inflammation associated with obesity led us to hypothesize that TNF-α blockade may have an effect on experimentally obese animals.

Aims: We studied the effects of thalidomide, an immunosuppressant and anti-TNF-α drug, on hepatic alterations that were induced by a high-fat diet (HFD) in mice.

Methods: Obesity was induced in Swiss mice using a HFD for 12 weeks. Thalidomide-treated animals received thalidomide i.p. (100 mg/kg/day, 10 days). Glucose, aspartate aminotransferases and alanine aminotransferases levels were assessed in the blood. Insulin and glucose tolerance tests were performed. The liver was excised for histological, triglyceride, gene and protein expression analyses.

Results: We found improvements in both the basal glucose blood levels and the response to insulin administration in the treated animals. The molecular analysis of insulin signalling revealed a restoration of the hepatic insulin receptor substrate (IRS)-1 and AKT phosphorylation. The hepatic expression of TNF-α was inhibited and the levels correlated with a significant reduction in the steatosis area. Other hepatic inflammatory markers, such as iNOS and suppressor of cytokine signalling (SOCS-3), were also reduced.

Conclusions: We suggest that immunosuppressant drugs that target TNF-α and that may also contribute to reductions in the inflammatory markers that are associated with obesity could be a therapeutic option in NAFLD and type 2 diabetes.